SCHEMBL29967647

SCHEMBL29967647

Cc1cn(-c2cc(NC(=O)c3ccc4c(c3)N(Cc3ccc5[nH]ncc5c3)CC4)cc(C(F)(F)F)c2)cn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 7/20 0.54
▸ BCR P11274 5/20 0.54
▸ DDR1 Q08345 8/20 0.53
▸ NTRK3 Q16288 4/20 0.53
▸ NTRK1 P04629 3/20 0.53
▸ NTRK2 Q16620 3/20 0.53
▸ DDR2 Q16832 5/20 0.52
▸ NR2E1 Q9Y466 3/20 0.52
▸ KIT P10721 2/20 0.51
▸ PDGFRB P09619 1/20 0.51
▸ MEN1 O00255 1/20 0.49
▸ OPRK1 P41145 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ EPHB2 P29323 1/20 0.49
▸ MUSK O15146 1/20 0.48
▸ CDK11B P21127 1/20 0.48
▸ EPHA8 P29322 1/20 0.48
▸ CDK11A Q9UQ88 1/20 0.48
▸ LDLR P01130 1/20 0.48
▸ PCSK9 Q8NBP7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27083082 1.00 ABL1 (0.54) ABL1BCRDDR1NTRK3NTRK1
SCHEMBL27081680 0.92 ABL1 (0.61) ABL1BCRDDR1NTRK3NTRK1
SCHEMBL27081687 0.88 DDR1 (0.54) ABL1BCRDDR1NTRK3NTRK1
SCHEMBL29967592 0.87 NR2E1 (0.53) ABL1BCRDDR1NTRK3NTRK1
SCHEMBL27081785 0.87 NR2E1 (0.53) ABL1BCRDDR1NTRK3NTRK1
SCHEMBL29939696 0.87 DDR1 (0.65) ABL1BCRDDR1NTRK3NTRK1
SCHEMBL27082304 0.87 DDR1 (0.65) ABL1BCRDDR1NTRK3NTRK1
SCHEMBL27081565 0.86 MAPK14 (0.54) ABL1BCRDDR1NTRK3NTRK1
SCHEMBL29967917 0.84 DDR1 (0.56) ABL1BCRDDR1NTRK3NTRK1
SCHEMBL27081377 0.84 DDR1 (0.56) ABL1BCRDDR1NTRK3NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP claimed
EP-4313972-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-02-07 — — EP claimed
CN-117062812-A Indoline derivatives as DDR inhibitors 奇斯药制品公司 2023-11-14 — — CN claimed
WO-2022200577-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-09-29 — — WO claimed
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP disclosed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 ABL1 284/4885BCR 1069/4885DDR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback